Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 19, 2025 -- For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall survival versus placebo + ENZA, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.
Neeraj Agarwal, M.D., from the Huntsman Cancer Institute at the University of Utah in Salt Lake City, and colleagues reported final overall survival (OS) data among patients with mCRPC unselected for HRR gene alterations who had improved radiographic progression-free survival with TALA + ENZA versus placebo + ENZA as first-line treatment in the phase 3 TALAPRO-2 trial.
A total of 805 patients were randomly assigned: 402 and 403 to TALA + ENZA and placebo + ENZA, respectively. At the data cutoff (Sept. 3, 2024), 52 and 60 percent of patients in the TALA + ENZA and placebo + ENZA arms, respectively, had died. The researchers found that the hazard ratio for OS was 0.796 (95 percent confidence interval, 0.661 to 0.958) for TALA + ENZA versus placebo + ENZA, with a median OS of 45.8 and 37.0 months, respectively. In patients who were HRR-deficient and in those who were HRR-nondeficient/unknown, OS favored TALA + ENZA versus placebo + ENZA (hazard ratios, 0.549 [95 percent confidence interval, 0.364 to 0.826] and 0.878 [95 percent confidence interval, 0.713 to 1.080], respectively). Updated radiographic progression-free survival data favored TALA + ENZA versus placebo + ENZA, consistent with the primary analysis (hazard ratio, 0.667; 95 percent confidence interval, 0.551 to 0.807).
"TALA + ENZA demonstrated a statistically significant and clinically meaningful improvement in OS versus standard-of-care ENZA," the authors write.
Several authors disclosed ties to Pfizer, which manufactures talazoparib.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Longer PSA Monitoring in Patients With Persistent PSA May Reduce Overtreatment
THURSDAY, March 27, 2025 -- Assessment of prostate-specific antigen (PSA) level for three months after radical prostatectomy (RP) for prostate cancer may minimize overtreatment...
Mobile Prostate Cancer Screening Clinic Can ID the Disease in Disadvantaged Men
TUESDAY, Feb. 18, 2025 -- A "Man Van" deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a study presented at the American...
Testosterone Recovery Linked to Overall Survival in High-Risk Prostate Cancer
TUESDAY, Feb. 18, 2025 -- Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients with high-risk prostate...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.